Tina Marriott Larson
Net Worth

Last updated:

What is Tina Marriott Larson net worth?

The estimated net worth of Ms. Tina Marriott Larson is at least $5,986,914 as of 24 Oct 2024. She owns shares worth $2,610,901 as insider, has earned $1,520,173 from insider trading and has received compensation worth at least $1,855,840 in Recursion Pharmaceuticals, Inc..

What is the salary of Tina Marriott Larson?

Ms. Tina Marriott Larson salary is $463,960 per year as Chief Operating Officer & Pres in Recursion Pharmaceuticals, Inc..

How old is Tina Marriott Larson?

Ms. Tina Marriott Larson is 50 years old, born in 1975.

What stocks does Tina Marriott Larson currently own?

As insider, Ms. Tina Marriott Larson owns shares in one company:

Company Title Shares Price per share Total value
Recursion Pharmaceuticals, Inc. (RXRX) Chief Operating Officer & Pres 521,138 $5.01 $2,610,901

What does Recursion Pharmaceuticals, Inc. do?

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

RXRX logo
RXRX
Recursion Pharmaceuticals, Inc.
$5.01

Tina Marriott Larson insider trading

Recursion Pharmaceuticals, Inc.

Ms. Tina Marriott Larson has made 24 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently she sold 6,000 units of RXRX stock worth $37,854 on 24 Oct 2024.

The largest trade she's ever made was exercising 58,500 units of RXRX stock on 4 Mar 2022. As of 24 Oct 2024 she still owns at least 521,138 units of RXRX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Class A Common Stock 6,000 $6.31 $37,854
Option
Stock Option (Right to Buy) 6,000 $1.06 $6,360
Option
Class A Common Stock 6,000 $1.06 $6,360
Option
Stock Option (Right to Buy) 0 $1.06 $0
Sale
Class A Common Stock 6,000 $7 $42,006
Option
Class A Common Stock 6,000 $1.06 $6,360
Option
Stock Option (Right to Buy) 6,000 $1.06 $6,360
Sale
Class A Common Stock 6,000 $7.56 $45,378
Option
Class A Common Stock 6,000 $1.06 $6,360
Option
Stock Option (Right to Buy) 3,000 $1.06 $3,180
Sale
Class A Common Stock 3,000 $7.67 $23,022
Option
Class A Common Stock 3,000 $1.06 $3,180
Option
Class A Common Stock 8,000 $1.06 $8,480
Sale
Class A Common Stock 7,390 $10.7 $79,066
Sale
Class A Common Stock 610 $11.34 $6,915
Option
Stock Option (Right to Buy) 8,000 $1.06 $8,480
Option
Class A Common Stock 8,000 $1.06 $8,480
Sale
Class A Common Stock 8,000 $14.9 $119,160
Option
Stock Option (Right to Buy) 8,000 $1.06 $8,480
Option
Stock Option (Right to Buy) 3,000 $1.06 $3,180
Sale
Class A Common Stock 3,000 $5.63 $16,884
Option
Class A Common Stock 3,000 $1.06 $3,180
Option
Stock Option (Right to Buy) 3,000 $1.06 $3,180
Option
Class A Common Stock 3,000 $1.06 $3,180
Sale
Class A Common Stock 3,000 $7.72 $23,160
Option
Class A Common Stock 3,000 $1.06 $3,180
Option
Stock Option (Right to Buy) 3,000 $1.06 $3,180
Sale
Class A Common Stock 63 $9.45 $596
Sale
Class A Common Stock 2,937 $8.64 $25,373
Option
Stock Option (Right to Buy) 8,000 $1.06 $8,480
Option
Class A Common Stock 8,000 $1.06 $8,480
Sale
Class A Common Stock 3,627 $13.12 $47,572
Sale
Class A Common Stock 4,373 $14.05 $61,423
Option
Stock Option (Right to Buy) 3,000 $1.06 $3,180
Option
Class A Common Stock 3,000 $1.06 $3,180
Sale
Class A Common Stock 3,000 $7.49 $22,470
Sale
Class A Common Stock 3,000 $8.63 $25,887
Option
Stock Option (Right to Buy) 3,000 $1.06 $3,180
Option
Class A Common Stock 3,000 $1.06 $3,180
Option
Class A Common Stock 8,000 $1.06 $8,480
Sale
Class A Common Stock 8,000 $8.07 $64,544
Option
Stock Option (Right to Buy) 8,000 $1.06 $8,480
Option
Stock Option (Right to Buy) 8,000 $1.06 $8,480
Sale
Class A Common Stock 8,000 $7.7 $61,568
Option
Class A Common Stock 8,000 $1.06 $8,480
Option
Stock Option (Right to Buy) 16,000 $1.06 $16,960
Option
Class A Common Stock 16,000 $1.06 $16,960
Sale
Class A Common Stock 16,000 $10.96 $175,408
Sale
Class A Common Stock 16,000 $10.72 $171,456
Option
Class A Common Stock 16,000 $1.06 $16,960
Option
Stock Option (Right to Buy) 16,000 $1.06 $16,960
Option
Class A Common Stock 16,000 $1.06 $16,960
Sale
Class A Common Stock 64 $11.53 $738
Sale
Class A Common Stock 15,936 $10.86 $173,017
Option
Stock Option (Right to Buy) 16,000 $1.06 $16,960
Option
Stock Option (Right to Buy) 16,000 $1.06 $16,960
Sale
Class A Common Stock 16,000 $12.6 $201,632
Option
Class A Common Stock 16,000 $1.06 $16,960
Option
Class A Common Stock 58,500 $1.06 $62,010
Option
Stock Option (Right to Buy) 58,500 $1.06 $62,010
Option
Stock Option (Right to Buy) 16,000 $1.06 $16,960
Option
Class A Common Stock 16,000 $1.06 $16,960
Option
Stock Option (Right to Buy) 4,000 $1.06 $4,240
Option
Class A Common Stock 4,000 $1.06 $4,240
Sale
Class A Common Stock 2,500 $19.01 $47,525
Sale
Class A Common Stock 2,500 $19.01 $47,520

Recursion Pharmaceuticals key executives

Recursion Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: